April 4, 2025, Washington, DC – Congressional Republicans today introduced three Congressional Review Act (CRA) resolutions that restricts states’ rights to establish robust tailpipe emission standards.
March 31, 2025: Washington, DC – The National Consumers League (NCL) is commending President Donald J. Trump for signing an Executive Order aimed at protecting fans from exploitative ticket scalping and implementing common sense reforms in the live entertainment ticketing industry. This decisive action underscores the urgent need for Congress to pass the bipartisan Transparency in Charges for Key Events Ticketing (TICKET) Act (S.281/H.R. 1402).
March 28, 2025: Washington, DC – The National Consumers League (NCL) strongly opposes efforts to rescind the Consumer Financial Protection Bureau’s (CFPB) new overdraft fee rule through the Congressional Review Act (CRA). This rule is a critical step in closing an outdated loophole that has allowed major banks to rake in billions from excessive overdraft fees—often at the expense of hardworking families living paycheck to paycheck.
March 27, 2025: Washington, DC – The National Consumers League (NCL) is deeply concerned by the Trump administration’s decision to lay off an additional 10,000 employees at the Department of Health and Human Services (HHS) following the already eliminated 10,000 jobs via previous rounds of cuts. In total, the restructuring and force reduction plans will result in a downsizing from 82,000 to 62,000 full-time employees nationwide.
March, 26, 2025: Washington, DC – The National Consumers League (NCL) celebrates the successful passage of the Child Marriage Prohibition Amendment Act of 2024, following the 30-day congressional review period and the signing of the legislation by Washington, DC, Mayor Muriel Bowser. This landmark law, introduced by Councilmember Brooke Pinto, now officially prohibits marriage under the age of 18 in the District of Columbia, with no exceptions.
March 25, 2025: Washington, DC — On Friday, The National Consumers League (NCL) and four other advocacy groups joined a legal “friend of the court” brief in litigation seeking to undo the Federal Trade Commission’s popular “Click to Cancel” Rule. The brief was drafted by the Center for Consumer Law & Economic Justice at UC Berkeley School of Law and focuses on the substantial record of manipulative subscription traps relied on by the FTC in crafting the Rule.
March 25, 2025: Washington, DC – The National Consumers League (NCL) is issuing an urgent warning to consumers regarding the recent bankruptcy filing by 23andMe, the popular genetic information company. While 23andMe claims that consumer data will be protected during the bankruptcy process, there are significant concerns about the future of your personal genetic data and health information.
March 21, 2025: The National Consumers League (NCL) is alarmed by the Trump administration’s recent decision to freeze a vital program designed to expand electric vehicle (EV) infrastructure and support clean energy initiatives across the country. The National Electric Vehicle Infrastructure (NEVI) program, created under the Biden administration, allocates nearly $5 billion to assist states in developing a national network of 500,000 electric vehicle charging stations along designated alternative fuel corridors.
March 21, 2025: Washington, DC — Today, the National Consumers League and 24 other public interest organizations urged leaders of the House Energy and Commerce and Senate Commerce committees to investigate President Trump’s attempt to fire half of the commissioners at the Federal Trade Commission. The groups also urged the Senate to freeze President Trump’s nomination of Mark Meador to be the newest commissioner at the FTC until Commissioners Alvaro Bedoya and Rebecca Slaughter regain full and permanent access to their Senate-confirmed positions.
March 19, 2025: Washington, DC – The National Consumers League (NCL) applauds West Virginia lawmakers for the passage of House Bill 2354. This bipartisan legislation amends the State Code regarding adulterated food and drugs, banning harmful food additives and dyes in processed food products sold in the state. Among the banned substances are Red Dye No. 3, Yellow Dye No. 5, Butylated Hydroxyanisole (BHA), Propylparaben, Red Dye No. 40, Yellow Dye No. 6, Blue Dye No. 1, Blue Dye No. 2, and Green Dye No. 3 – all deemed unsafe for consumption.
The work of the National Consumers League is making a difference in people’s lives across the country. Meet some of the consumers touched by our programs.
Read about NCL’s impact
Paige, 55, a Nashville wife and mother of two, answered an employment ad for secret shoppers. Before sending payment to the scammers, she reached out to NCL.
Read about NCL’s impact
A grease fire flared up in Decklan’s kitchen. As his family scrambled and panicked, fearing that the whole house might erupt in flames, Decklan remained calm. He hurried over to the pantry, grabbed some baking soda, and dumped it on the fire quickly extinguishing the blaze.
Read about NCL’s impact
Cincinnati resident Charles, 45, lost his computer business — and health insurance— during a time of economic downturn. A diabetic, Charles was now unable to afford his medication. He stopped taking it which made him seriously ill and put his life at risk.
Read about NCL’s impact
Jeremy is a fast-food worker who has been employed at a number of Chipotle restaurants in New York City. When he was just 20 years old, he took part in an NCL research project that revealed that management practices within the fast food chain were putting workers—and food safety for customers—at risk.
Read about NCL’s impact
By Sally Greenberg, NCL Executive Director
While the COVID-19 pandemic has led to hardship for all Americans, it is clear that people of color have been disproportionately burdened. Across the health care continuum, addressing this disparity has become part of the broader conversation about the history of systemic racism and the underlying social determinants of health that negatively affect the mental, physical, and economic health of individuals and entire communities.
The pandemic has underscored persistent health disparities, and there is growing recognition that representation in research and clinical trials can have a profound impact on health outcomes. A lack of representation from racially and ethnically diverse groups in research and clinical trials have typically led to gaps in data, missing the opportunity to assess the full impact of various treatments and drugs across a range of populations. The collection and use of real-world research and data to inform the potential use, risks, and benefits of medical products and treatments can ultimately lead to better health outcomes, particularly for those who have been underrepresented in the past.
Existing efforts to improve inclusion
Efforts to expand diversity and representation in medical research are underway in Congress. Policymakers are encouraging the incorporation of Real World Evidence (RWE) in drug development through the recent Cures 2.0 draft legislation released by Reps. Diana Degette (D-CO-1) and Fred Upton (D-MI-6). While the status quo limits us from effectively reaching underserved populations, the proposed legislation would allow studies that include RWE for some drugs after they have been approved. At the heart of this issue is a growing appreciation that the same therapy can affect different populations in different ways, which is why Cures 2.0 supports collecting data that more accurately reflects the unique experiences and needs of patients across diverse populations.
Recognizing the potential for RWE in maternal health
The lack of representative research in the field of maternal health is undeniable, and its implications are staggering. The dismal state of maternal care in the United States reflects how our health care system has failed women of color, including by not adequately studying treatment options to prevent maternal morbidity and mortality. The need for RWE is clear when you consider the persistent disparities in health outcomes that plague minority communities.
Preterm birth and its disproportionate impact on women of color is a stark illustration of the need to make progress on representative research in maternal health. Preterm birth is the second-largest contributor to infant death in America today. Despite the tremendous physical, emotional, and financial toll that preterm birth continues to take on our country — disproportionately so on women and families of color — not enough therapeutic tools currently exist to prevent it.
Today, “17P,” the only FDA-approved treatment to help reduce the likelihood of spontaneous, recurrent preterm birth in the United States is at-risk of being withdrawn from the market in all its forms, including the branded product and five generic versions. Unfortunately there is conflicting evidence from two different clinical trials, one representative of a diverse U.S. population and another studied in a largely white population in Europe. It’s not a straightforward comparison. If 17P is withdrawn, the women most affected by preterm birth, predominantly women of color, would be left without an FDA-approved treatment option.
The FDA is considering the path forward, including additional data collection through leveraging RWE from past patient use. The success of the first (approval) trial for 17P in the impacted communities signals the importance of RWE. Continued access to 17P is, at its core, a matter of health equity. Black women must not yet again be left vulnerable to a system that historically has overlooked them.
